**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 87343

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Effects and mechanisms of nutritional interventions on extradigestive complications in obese patients**

Jiang L *et al.* Nutrition and extradigestive complications in obesity

Li Jiang, Lu-Lian Xu, Yang Lu, Ke-Feng Gu, Shu-Yi Qian, Xi-Ping Wang, Xu Xu

**Li Jiang, Lu-Lian Xu, Yang Lu, Ke-Feng Gu, Shu-Yi Qian, Xi-Ping Wang, Xu Xu,** Department of Endocrine, Wuxi Children’s Hospital, Wuxi 214023, Jiangsu Province, China

**Co-first authors:** Li Jiang and Lu-Lian Xu.

**Author contributions:** Jiang L, Xu LL, Lu Y, Gu KF, Qian SY, Wang XP, and Xu X designed the research study; Jiang L, Xu LL, Lu Y, Gu KF, Qian SY, Wang XP, and Xu X performed the research; Jiang L, Xu LL, and Xu X contributed new reagents and analytic tools; Jiang L, Xu LL, and Xu X analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript. Jiang L and Xu LL contributed equally to this work as co-first authors. The reasons for designating Jiang L and Xu LL as co-first authors are threefold. First, the research was performed as a collaborative effort, and the designation of co-first authors accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. This also ensures effective communication and management of post-submission matters, ultimately enhancing the paper's quality and reliability. Second, the overall research team encompassed authors with a variety of expertise and skills from different fields, and the designation of co-first authors best reflects this diversity. This also promotes the most comprehensive and in-depth examination of the research topic, ultimately enriching readers' understanding by offering various expert perspectives. Third, Jiang L and Xu LL contributed efforts of equal substance throughout the research process. The choice of these researchers as co-first authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. In summary, we believe that designating Jiang L and Xu LL as co-first authors of is fitting for our manuscript as it accurately reflects our team's collaborative spirit, equal contributions, and diversity.

**Supported by** Wuxi Municipal Health Commission Maternal and Child Health Research Project, No. FYKY202206.

**Corresponding author: Xu Xu, MD, Attending Doctor,** Department of Endocrine, Wuxi Children’s Hospital, No. 299 Qingyang Road, Liangxi District, Wuxi 214023, Jiangsu Province, China. xuxu02202@126.com

**Received:** August 30, 2023

**Revised:** September 22, 2023

**Accepted:** October 23, 2023

**Published online:** November 27, 2023

**Abstract**

BACKGROUND

Obesity is associated with an increased risk of multiple extradigestive complications. Thus, understanding the global epidemiology of obesity and its relationship with extradigestive complications, such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease is important. However, nutritional intervention can positively manage issues associated with obesity. Hence, the identification of the current high prevalence of extradigestive complications among patients with obesity and the potential role of nutritional interventions is also essential.

AIM

To determine the relationship between obesity and extradigestive complications and emphasize the importance of nutritional interventions in the management of patients with obesity.

METHODS

Overall, 110 patients with obesity admitted to our hospital from February 2020 to November 2022 and 100 healthy individuals were included in the present study. Information of the study population, including demographic characteristics, such as age, sex, body mass index, indicators of extradigestive complications, dietary intake, and biomarkers was collected. The study design, participant selection, interventions, and development of the nutritional intervention program were described. The collected data were analyzed to assess the effect of nutritional interventions on extradigestive complications.

RESULTS

As a part of nutritional intervention, the dietary structure was modified to decrease the saturated fatty acid and cholesterol intake and increase the dietary fiber and polyunsaturated fatty acid intake to improve the blood lipid levels and cardiovascular health. Mechanistic studies showed that these nutritional interventions positively affected mechanisms that regulate lipid metabolism, improved inflammatory markers in the blood, and improved vascular functions.

CONCLUSION

The study discusses the consistency of the present results with previous findings to assess the clinical significance of the present findings. The study provides direction for future research on improving nutritional intervention strategies.

**Key Words:** Obesity; Nutritional interventions; Extradigestive complications; Cardiovascular disease; Type 2 diabetes; Non-alcoholic fatty liver disease

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Jiang L, Xu LL, Lu Y, Gu KF, Qian SY, Wang XP, Xu X. Effects and mechanisms of nutritional interventions on extradigestive complications in obese patients. *World J Gastrointest Surg* 2023; 15(11): 2482-2489

**URL:** https://www.wjgnet.com/1948-9366/full/v15/i11/2482.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v15.i11.2482

**Core Tip:** Nutritional interventions positively impact extradigestive complications in patients with obesity by modifying the dietary structure to improve lipid metabolism, inflammatory markers, and vascular functions. These findings emphasize the importance of nutritional interventions in managing obesity-related conditions, such as cardiovascular disease, type 2 diabetes, and non-alcoholic fatty liver disease, providing valuable insights for future research on optimizing intervention strategies.

**INTRODUCTION**

Obesity is a metabolic disease correlated to an increased risk of multiple extradigestive complications. Nutritional intervention, a crucial management tool, can positively affect weight management, associated disease risk control, and the occurrence of extradigestive complications in patients with obesity by modifying the dietary structure and providing appropriate nutrients[1-5]. The global prevalence of obesity is increasing and is closely related to the development of extradigestive complications, such as cardiovascular disease (CVD), type 2 diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD). Thus, nutritional intervention is clinically important as a nonpharmacological treatment strategy. By modifying the dietary structure and providing appropriate nutrients, nutritional interventions can help with weight management, control of the risk of associated diseases, and reduction in the occurrence of extradigestive complications[6-8].

Introduction to obesity and its worldwide epidemiological data and trends: The relationship between obesity and extradigestive complications has been discussed, highlighting their relevance and importance. Nutritional interventions are important tools for managing patients with obesity patients and preventing complications[9-11]. The association between CVD and obesity has been studied. Nutritional intervention strategies, such as limiting the energy intake, modifying fat and cholesterol intake, and increasing the dietary fiber and polyunsaturated fatty acid (PUFA) intake, are essential to reduce the risk of CVDs. The underlying mechanisms, such as improved lipid metabolism, reduced inflammatory responses, and improved vascular function may help achieve the desired effect of nutritional interventions. Furthermore, nutritional intervention strategies may play a role in improving the insulin sensitivity and glucose metabolism by controlling the glycemic response, weight management, and high-sugar food intake. The possible underlying mechanisms are improving insulin signaling, reduced insulin resistance, and fat accumulation. Additionally, nutritional intervention strategies may play a role in improving hepatic fat accumulation and reducing hepatic inflammation and fibrosis by reducing the fat and sugar intake and increasing the intake of dietary fiber and antioxidants. The possible underlying pathways may be the modulation of fatty acid synthesis and oxidation, amelioration of the hepatic inflammatory response, and reduction in oxidative stress. To summarize the important findings of studies on the effects and mechanisms of nutritional interventions on extradigestive complications in patients with obesity[12-15]. Thus, in the present study, we aimed to investigate the effect of nutritional interventions on extradigestive complications in patients with obesity and the mechanisms underlying this effect. Furthermore, we emphasized the potential and importance of nutritional interventions in preventing and managing obesity and obesity-related complications.

**MATERIALS AND METHODS**

***Research design***

The present study was conducted on 110 patients with obesity admitted to our hospital from February 2020 to November 2022 and 100 normal individuals. We selected the study design of “randomized controlled trial” to evaluate the effects and mechanisms of nutritional interventions on extradigestive complications in patients with obesity. The participants were randomized into the following two groups: An intervention group and a control group.

***Research subjects***

Patients with obesity meeting the following criteria were selected as study subjects: age range, 18-60 years, and diagnostic criterion, body mass index (BMI) ≥ 30 kg/m². The exclusion criteria were as follows: Patients with other important underlying diseases, including metabolic diseases and CVDs and patients undergoing other interventions, such as taking medications for other health conditions.

***Nutritional intervention program***

In the intervention group, a specific nutritional intervention program was implemented, which involved the following: Energy control: Individualized energy intake targets were set based on the participants’ body composition, activity levels, and metabolic needs and dietary composition. The diets of the participants were modified to limit saturated fatty acid (SFA) and cholesterol intake and increase the dietary fiber and PUFA intake. Nutritional education and individualized dietary guidance were provided to help the patients understand and adopt healthy eating habits. The control group received routine standard care and non-interventional general advice such as general dietary guidance or lifestyle advice.

***Observation indicators***

(1) Pre and post-intervention data collection included, but was not limited to, the following demographic characteristics: age, sex, and BMI; (2) Indicators of extradigestive complications included information on the occurrence and severity of several extradigestive complications associated with obesity, such as the indicators of CVD risk, diabetes mellitus, and liver function; (3) Dietary intake data: Information on the patients’ diets, including energy, fat, fiber, and other nutrients, was collected using the methods of recording food intake or dietary review, and (4) Biomarkers: Blood markers, such as lipid and blood glucose levels, liver function indicators, and urine markers.

***Data analysis***

Means and standard deviations were calculated to statistically analyze the demographic characteristics of the groups and baseline data. Changes in the indicators of extradigestive complications between the intervention and control groups were compared by statistical methods, such as the independent samples *t*-test and chi-square test. The relationship between the indicators of extradigestive complications and dietary intake data after the intervention was explored by calculating the pearson’s correlation coefficient. Differences were considered statistically significant at *P* < 0.05.

**RESULTS**

***General information***

No statistically significant difference was observed between the intervention and control groups in terms of age (52.4 ± 1.0 years) *vs.* (51.2 ± 1.3 years), body weight, BMI, literacy level, and the monthly household income (*P* > 0.05). No difference was observed regarding the use of antihypertensive medications between the two groups at baseline. The dosage and frequency of drug consumption remained unchanged for the subjects throughout the trial, and no adverse effects or reactions were reported. None of the participants withdrew from the study for any reason. The baseline characteristics of the patients are summarized in Table 1.

***Indicators of CVD risk***

No difference in diastolic blood pressure was observed between the subjects in the two groups after the intervention, whereas the systolic blood pressure of the subjects in the intervention group was lower than that of the subjects in the control group (*P* < 0.05). After four weeks of dietary intervention, the systolic and diastolic blood pressures of the subjects in both groups decreased; however, the decrease observed in the intervention group was more pronounced, with a statistically significant difference (Table 2).

***Nutrient intake of subjects in the control and intervention groups***

The mean intake of protein, carbohydrates, dietary fiber, potassium, calcium, and magnesium in the intervention group was higher than that in the control group. Additionally, the mean intake of energy, fat, cholesterol, SFA, monounsaturated fatty acid, PUFA, and sodium in the intervention group was lower than that in the control group (*P* < 0.05 for both) (Table 3).

***Comparison of liver function indices between the two groups before and after intervention***

No statistically significant differences in the serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels were observed between the intervention and control groups before the intervention. After four weeks of dietary intervention, the ALT and AST levels in the intervention group were lower than those before the intervention, and the differences were statistically significant (*P* < 0.05) (Table 4).

***Logistic multifactorial regression analysis of factors affecting the occurrence of extradigestive complications in patients with obesity***

A logistic multifactorial regression analysis was performed on the dependent variables associated with extradigestive complications that occurred in patients with lacunar cerebral infarction. The indices with *P* < 0.05 in the above univariate analysis were used as independent variables. The results showed that a history of high blood pressure and high levels of low-density lipoprotein-C, platelet endothelial cell adhesion molecule (PECAM)-1, and fibroblast growth factor (FGF)21 were identified as risk factors for extradigestive complication occurrence in patients with lacunar cerebral infarction (*P* < 0.01), whereas high levels of low-density lipoprotein (HDL)-C and growth differentiation factor (GDF)11 were identified as protective factors (*P* < 0.05). High levels of HDL-C, PECAM-1, and FGF21 were identified as risk factors for extradigestive complication development in patients with lacunar cerebral infarction (*P* < 0.01), whereas high levels of serum HDL-C and GDF11 were identified as protective factors (*P* < 0.05) (Table 5).

***Diagnostic value of serum PECAM-1, GDF11, and FGF21 levels for extradigestive complications in patients with obesity***

The receiver operating characteristic (ROC) curve showed that the area under the curve (AUC) values of serum PECAM-1, GDF11, and FGF21 levels as well as the combination of these three diagnostic indicators for carotid atherosclerosis were 0.798, 0.716, 0.813, and 0.909, respectively. Furthermore, the efficacy of the combination was higher than that of each indicator alone (Z/*P* = 2.097/0.036, 2.290/0.022, 2.005/0.045, 022, and 2.005/0.045) (Table 6).

**DISCUSSION**

Patients with obesity often show symptoms, such as high blood pressure, cholesterol, and blood glucose levels, which are considered CVD risk factors[16-18]. Nutritional interventions, such as limiting the energy intake and improving diet quality can reduce the risk of CVD. For instance, reducing the saturated fat and cholesterol intake, and increasing the dietary fiber and whole grain intake can help improve lipid and glycemic control.

Patients with obesity often suffer from disease. Nutritional interventions, such as limiting the energy intake can improve NAFLD by improving the lipid metabolism and reducing liver fat accumulation. A diet limiting the consumption of high-sugar and high-fat foods, increasing the antioxidant and anti-inflammatory food intake, and reducing alcohol consumption can positively affect liver health[19].

Obesity is an important risk factor of insulin resistance and type 2 diabetes. Nutritional interventions that reduce the energy intake, control the carbohydrate intake, and aid in the consumption of foods with a low glycemic index can reduce the risk of insulin resistance and diabetes by improving insulin sensitivity[20].

Finally, the ROC curve analysis showed that the serum levels of PECAM-1, GDF11, and FGF21 possessed high diagnostic values for extradigestive complications in patients with obesity, and the diagnostic value was further improved when the combination of the three indicators was considered (AUC = 0.909). The diagnostic sensitivity, specificity, and accuracy of the combination were 0.919, 0.884, and 0.900, respectively. Nutritional intervention is a clinically important non-pharmacological treatment strategy. By modifying the dietary structure and providing appropriate nutrients, nutritional interventions help control body weight, manage the risk of associated diseases, and reduce the incidence of extragastrointestinal complications. Despite the creativity of the study, it is not yet possible to list all the possibilities due to the limitations of the sample size and research model; future studies should expand the sample size and age structure to exclude these limitations.

**CONCLUSION**

In conclusion, the levels of PECAM-1, GDF11, and FGF21 are related to cerebral arterial hemodynamic parameters in extradigestive complications in patients with obesity; thus, they can be considered as factors affecting the extradigestive complications in patients with obesity. Moreover, the combination of the three has a better diagnostic value for extradigestive complications in patients with obesity.

**ARTICLE HIGHLIGHTS**

***Research background***

Obesity is associated with an increased risk of multiple extradigestive complications. Thus, understanding the global epidemiology of obesity and its relationship with extradigestive complications, such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease, is important. Nutritional interventions can also positively manage obesity-associated issues.

***Research motivation***

In the present study, we aimed to determine the relationship between obesity and extradigestive complications and emphasize the importance of nutritional interventions in managing patients with obesity.

***Research objectives***

Hence, identification of the current high prevalence of extradigestive complications among patients with obesity and the potential role of nutritional interventions are essential.

***Research methods***

Overall, 110 patients with obesity admitted to our hospital from February 2020 to November 2022 and 100 healthy individuals were included in the present analysis. Information regarding demographic characteristics, such as age, sex, body mass index, indicators of extradigestive complications, dietary intake, and biomarkers, was collected. The study design, participant selection, interventions, and development of the nutritional intervention program were described. The collected data were analyzed to assess the effects of nutritional interventions on extradigestive complications.

***Research results***

As part of the nutritional intervention, the dietary structure was modified to decrease the saturated fatty acid and cholesterol intake and increase the dietary fiber and polyunsaturated fatty acid intake to improve the blood lipid levels and cardiovascular health. Mechanistic studies have shown that nutritional interventions positively affect mechanisms that regulate lipid metabolism, improve inflammatory markers in the blood, and improve vascular function.

***Research conclusions***

The present study explains the possible mechanisms by which nutritional interventions affect extradigestive complications in patients with obesity. Moreover, we discuss the consistency of the present results with previous findings to assess the clinical significance of the present findings.

***Research perspectives***

The study provides directions for future research on improving nutritional intervention strategies.

**REFERENCES**

1 **Bao N**, Liu X, Zhong X, Jia S, Hua N, Zhang L, Mo G. Dapagliflozin-affected endothelial dysfunction and altered gut microbiota in mice with heart failure. *PeerJ* 2023; **11**: e15589 [PMID: 37520255 DOI: 10.7717/peerj.15589]

2 **Yusuf S**, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; **364**: 937-952 [PMID: 15364185 DOI: 10.1016/S0140-6736(04)17018-9]

3 **Benjamin EJ**, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation* 2019; **139**: e56-e528 [PMID: 30700139 DOI: 10.1161/CIR.0000000000000659]

4 **Liu C**, Luo YP, Chen J, Weng YH, Lan Y, Liu HB. Functional polymorphism in miR-208 is associated with increased risk for ischemic stroke. *BMC Med Genomics* 2023; **16**: 176 [PMID: 37525251 DOI: 10.1186/s12920-023-01610-y]

5 **Yeh HW**, Chung CT, Chang CK, Yeh CB, Wang BY, Lee CY, Wang YH, Yeh LT, Yang SF. Association of Glaucoma with the Risk of Peripheral Arterial Occlusive Disease: A Retrospective Population-Based Cohort Study. *J Clin Med* 2023; **12** [PMID: 37510915 DOI: 10.3390/jcm12144800]

6 **Whyne EZ**, Woo J, Jeon-Slaughter H. The Effects of Subjective Wellbeing and Self-Rated Health on Lifetime Risk of Cardiovascular Conditions in Women. *Int J Environ Res Public Health* 2023; **20** [PMID: 37510612 DOI: 10.3390/ijerph20146380]

7 **Lee KP**, Huang HC, Tsai JY, Hsu LC. Effects of cancer on stroke recurrence and mortality: A single-center retrospective cohort study. *eNeurologicalSci* 2023; **32**: 100474 [PMID: 37522033 DOI: 10.1016/j.ensci.2023.100474]

8 **Simonin A**, Bangash O, Henley D, Bala A. Endonasal endoscopic resection of suprasellar craniopharyngioma: A retrospective single-center case series. *J Clin Neurosci* 2020; **81**: 436-441 [PMID: 33222959 DOI: 10.1016/j.jocn.2020.07.053]

9 **Williams B**, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members:. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens* 2018; **36**: 1953-2041 [PMID: 30234752 DOI: 10.1097/HJH.0000000000001940]

10 **Ciardullo S**, Zerbini F, Cannistraci R, Muraca E, Perra S, Oltolini A, Perseghin G. Differential Association of Sex Hormones with Metabolic Parameters and Body Composition in Men and Women from the United States. *J Clin Med* 2023; **12** [PMID: 37510898 DOI: 10.3390/jcm12144783]

11 **Sotos-Prieto M**, Bhupathiraju SN, Mattei J, Fung TT, Li Y, Pan A, Willett WC, Rimm EB, Hu FB. Association of Changes in Diet Quality with Total and Cause-Specific Mortality. *N Engl J Med* 2017; **377**: 143-153 [PMID: 28700845 DOI: 10.1056/NEJMoa1613502]

12 **Schwingshackl L**, Hoffmann G, Lampousi AM, Knüppel S, Iqbal K, Schwedhelm C, Bechthold A, Schlesinger S, Boeing H. Food groups and risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. *Eur J Epidemiol* 2017; **32**: 363-375 [PMID: 28397016 DOI: 10.1007/s10654-017-0246-y]

13 **Micha R**, Peñalvo JL, Cudhea F, Imamura F, Rehm CD, Mozaffarian D. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. *JAMA* 2017; **317**: 912-924 [PMID: 28267855 DOI: 10.1001/jama.2017.0947]

14 **Yang C**, Shi X, Xia H, Yang X, Liu H, Pan D, Sun G. The Evidence and Controversy Between Dietary Calcium Intake and Calcium Supplementation and the Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Cohort Studies and Randomized Controlled Trials. *J Am Coll Nutr* 2020; **39**: 352-370 [PMID: 31625814 DOI: 10.1080/07315724.2019.1649219]

15 **Lippi G**, Franchini M, Favaloro EJ. Pharmacogenetics of vitamin K antagonists: useful or hype? *Clin Chem Lab Med* 2009; **47**: 503-515 [PMID: 19397481 DOI: 10.1515/CCLM.2009.140]

16 **Timmers S**, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MKC, Kunz I, Schrauwen-Hinderling VB, Blaak E, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. *Cell Metab* 2011; **14**: 612-622 [PMID: 22055504 DOI: 10.1016/j.cmet.2011.10.002]

17 **Filippou CD**, Tsioufis CP, Thomopoulos CG, Mihas CC, Dimitriadis KS, Sotiropoulou LI, Chrysochoou CA, Nihoyannopoulos PI, Tousoulis DM. Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Adv Nutr* 2020; **11**: 1150-1160 [PMID: 32330233 DOI: 10.1093/advances/nmaa041]

18 **Cross AJ**, Leitzmann MF, Gail MH, Hollenbeck AR, Schatzkin A, Sinha R. A prospective study of red and processed meat intake in relation to cancer risk. *PLoS Med* 2007; **4**: e325 [PMID: 18076279 DOI: 10.1371/journal.pmed.0040325]

19 **Sinha R**, Cross AJ, Graubard BI, Leitzmann MF, Schatzkin A. Meat intake and mortality: a prospective study of over half a million people. *Arch Intern Med* 2009; **169**: 562-571 [PMID: 19307518 DOI: 10.1001/archinternmed.2009.6]

20 **Rees K**, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, Das A, Hartley L, Stranges S. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2019; **3**: CD009825 [PMID: 30864165 DOI: 10.1002/14651858.CD009825.pub3]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the WuXi Children’s Hospital.

**Informed consent statement:** All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 30, 2023

**First decision:** September 13, 2023

**Article in press:** October 23, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

1. **Reviewer:** Dubus P, France; Topi S, Italy **S-Editor:** Qu XL **L-Editor:** A  **P-Editor:** Qu XL

**Table 1 Baseline characteristics of the control and intervention groups (mean ± SE)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variant** | **Control group (*n* = 110)** | **Intervention group (*n* = 110)** | ***P* value** |
| Age (yr) | 28-63 (51.2 ± 1.3) | 36-68 (52.4 ± 1.0) | 0.488 |
| Sex [cases (%)] |  |  |  |
| Males | 25 (22.73) | 27 (24.55) | 0.605 |
| Females | 85 (77.27) | 83 (75.45) |  |
| Weight (kg) | 67.7 ± 1.7 | 69.2 ± 1.6 | 0.526 |
| Height (cm) | 170.7 ± 1.4 | 172.4 ± 1.3 | 0.385 |
| BMI (kg/m2) | 25.1 ± 0.4 | 25.1 ± 0.4 | 0.959 |
| SBP (mmHg) | 141.4 ± 1.4 | 141.9 ± 1.4 | 0.788 |
| DBP (mmHg) | 89.7 ± 1.5 | 89.5 ± 1.7 | 0.913 |
| MDA (nmol/L) | 4.24 ± 1.7 | 4.74 ± 1.5 | 0.196 |
| GSH (μmol/L) | 7.95 ± 3.2 | 6.93 ± 3.4 | 0.251 |
| SOD (U/mL) | 74.21 ± 12.3 | 67.66 ± 13.4 | 0.051 |
| Heart rate (time/min) | 78.1 ± 1.6 | 78.9 ± 1.3 | 0.693 |
| 1Educational level | 3:16:16 | 4:18:14 | 0.827 |
| 2Monthly household income | 8:14:13 | 6:15:15 | 0.799 |

1University/undergraduate and above: High school/junior high school: primary school and below.

2$20,000 and above: $10,000 to $20,000:$10,000 and below. BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MDA: Mobile device assistant; GSH: Glutathione; SOD: Superoxide dismutase.

**Table 2 Post-intervention changes in the blood pressure between the intervention and control groups (mean ± SE)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Norm** | **Control subjects** | | **Intervention group** | ***P* value** |
| DBP (mmHg) | Start of intervention | 86.4 ± 1.4 | 83.9 ± 1.7 | 0.241 |
|  | End of intervention | 82.8 ± 1.6 | 76.6 ± 1.6 | 0.007 |
|  | Amount of change before and after intervention | 3.6 ± 1.1 | 7.3 ± 1.1 | 0.000 |
| SBP (mmHg) | Start of intervention | 137.3 ± 1.4 | 133.2 ± 1.1 | 0.021 |
|  | End of intervention | 131.1 ± 1.6 | 116.3 ± 1.5 | 0.000 |
|  | Amount of change before and after intervention | 6.2 ± 2.0 | 16.9 ± 1.4 | 0.022 |

SBP: Systolic blood pressure; DBP: Diastolic blood pressure.

**Table 3 Nutrient intake in the control and intervention groups (mean ± SE)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Original proposal** | **Control subjects** | **Intervention group** | ***P* value** |
| Energy (kcal) | 2033.74 ± 19.45 | 1953.01 ± 18.55 | 0.036 |
| Fat (g) | 94.21 ± 1.13 | 50.79 ± 0.75 | 0.001 |
| Protein (g) | 76.42 ± 0.97 | 97.72 ± 0.89 | 0.017 |
| Carbohydrates (g) | 226.79 ± 3.29 | 275.03 ± 4.21 | 0.029 |
| Dietary fiber (g) | 10.28 ± 0.11 | 25.22 ± 1.59 | 0.005 |
| Cholesterol (mg) | 554.96 ± 3.84 | 473.30 ± 7.33 | 0.012 |
| SFA (g) | 47.58 ± 1.21 | 27.83 ± 0.28 | 0.006 |
| MUFA (g) | 29.5 ± 0.37 | 12.44 ± 0.10 | 0.001 |
| PUFA (g) | 20.20 ± 0.21 | 12.34 ± 0.28 | 0.013 |
| Sodium (mg) | 4347.28 ± 46.34 | 2284.86 ± 12.43 | 0.001 |
| Potassium (mg) | 1663.15 ± 11.14 | 3088.78 ± 67.37 | 0.001 |
| Calcium (mg) | 483.84 ± 14.09 | 864.32 ± 21.60 | 0.001 |
| Magnesium (mg) | 259.97 ± 2.28 | 479.05 ± 14.12 | 0.014 |

SFA: Saturated fatty acid; MUFA: Modulation of fatty acid; PUFA: Polyunsaturated fatty acid.

**Table 4 Comparison of the levels of oxidative stress indicators between the intervention and control groups (mean ± SE)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Norm** | **Control subjects** | | **Intervention group** | ***P* value** |
| ALT (nmol/L) | End of intervention | 115.29 ± 1.2 | 63.94 ± 1.4 | 0.001 |
|  | Amount of change before and after intervention | 21.25 ± 0.2 | 20.6 ± 0.1 | 0.015 |
| AST (μmol/L) | End of intervention | 157.15 ± 3.5 | 59.00 ± 2.8 | 0.017 |
|  | Amount of change before and after intervention | 20.6 ± 0.2 | 22.17 ± 0.1 | 0.021 |

ALT: Alanine transaminas; AST: Aspartate aminotransferase.

**Table 5 Logistic multifactorial regression analysis of factors affecting the occurrence of extradigestive complications in patients with obesity**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **β-value** | **SE value** | **Wald value** | **P value** | **OR value** | **95%CI** |
| History of hypertension | 1. 296 | 0.421 | 9.470 | 0.002 | 3.654 | 1.601-8.343 |
| TC high | 0.226 | 0.138 | 2.685 | 0.101 | 1. 254 | 0.957-1.643 |
| TG high | 0.305 | 0.211 | 2.091 | 0.148 | 1. 356 | 0.897-2.051 |
| HDL-C high | -0.247 | 0.123 | 4.002 | 0.045 | 0.781 | 0.613-0.995 |
| LDL-C high | 0.909 | 0.254 | 12.787 | < 0.001 | 2.481 | 1.508-4.085 |
| PECAM-1 high | 0.070 | 0.019 | 12.930 | < 0.001 | 1.073 | 1.032-1.114 |
| GDF11 high | -0.008 | 0.003 | 9.199 | 0.002 | 0.992 | 0.987-0.997 |
| FGF21 high | 0.024 | 0.007 | 13.062 | < 0.001 | 1. 024 | 1.011-1.038 |

OR: Odds ratio; CI: Confidenceinterval; TC: Total cholesterol; TG: Triacylglycerol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholestero; PECAM-1: Platelet endothelial cell adhesion molecule-1; GDF11: Growth differentiation factor 11; FGF21: Fibroblast growth factor 21.

**Table 6 Receiver operating characteristic curve analysis of the serum levels of platelet endothelial cell adhesion molecule-1, growth differentiation factor 11, and fibroblast growth factor 21 in predicting the occurrence of extradigestive complications in patients with obesity**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Indicators** | **Cut-of value** | **AUC (95%CI)** | **Sensitivity** | **Specificity** | **Jordon index** |
| PECAM-1 | 40 μg/L | 0.798 (0.595-0.974) | 0.824 | 0.744 | 0.568 |
| GDF11 | 650 μg/L | 0.716 (0.509 -0.929) | 0.716 | 0.733 | 0.449 |
| FGF21 | 160 ng/L | 0.813 (0.671-0.940) | 0.811 | 0.791 | 0.602 |
| Tripartite |  | 0.909 (0.850-0.958) | 0.919 | 0.884 | 0.803 |

AUC: Area under the curve; CI: Confidenceinterval; PECAM-1: Platelet endothelial cell adhesion molecule-1; GDF11: Growth differentiation factor 11; FGF21: Fibroblast growth factor 21.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**